Fondazione Ricerca Traslazionale

This study is testing whether combining the targeted drug amivantamab with a single chemotherapy drug can help control advanced lung cancer in patients who have a specific genetic mutation and cannot tolerate standard platinum-based chemotherapy. The trial will enroll 33 adults w…

This study is for people with a specific type of advanced lung cancer (stage III NSCLC) that has returned or gotten worse after they completed a standard treatment plan involving chemotherapy, radiation, and a drug called durvalumab. The trial is testing if adding durvalumab, and…

This study is testing whether adding a second drug called OSE2101 to standard maintenance therapy can better clear tiny traces of cancer from the blood of advanced lung cancer patients. It involves 160 patients who have a specific genetic marker and have already completed initial…

This trial is testing a treatment plan for stage III non-small cell lung cancer. It combines chemotherapy and immunotherapy to try to shrink tumors before surgery. The goal is to see if this approach helps more patients have successful, complete tumor removal. After surgery, pati…

This study aims to understand how lung cancer patients' immune systems respond to immunotherapy drugs. Researchers will track whether patients develop antibodies against their immunotherapy medications and whether these antibodies affect treatment effectiveness or side effects. T…